| CUBT Stock | | | USD 0.01 0.01 33.75% |
Chairman
Paul Michaels is President Chairman of Curative Biotechnology
| Age | 58 |
| Address | 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410 |
| Phone | 561 907 8990 |
| Web | https://curativebiotech.com |
Curative Biotechnology Management Efficiency
The company has return on total asset
(ROA) of
(0.5178) % which means that it has lost $0.5178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(3.9828) %, meaning that it created substantial loss on money invested by shareholders. Curative Biotechnology's management efficiency ratios could be used to measure how well Curative Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Curative Biotechnology's
Return On Capital Employed is comparatively stable compared to the past year.
Return On Equity is likely to gain to 1.75 in 2025, despite the fact that
Return On Tangible Assets are likely to grow to
(4.21).
Total Current Liabilities is likely to gain to about 6.9
M in 2025.
Liabilities And Stockholders Equity is likely to gain to about 3.1
M in 2025
Curative Biotechnology currently holds 2.26
M in liabilities with Debt to Equity
(D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Curative Biotechnology, Inc. operates as a development-stage biomedical company. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida. Curative Biotechnology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people. Curative Biotechnology (CUBT) is traded on NYSE MKT Exchange in USA and employs 4 people. Curative Biotechnology is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Curative Biotechnology Leadership Team
Elected by the shareholders, the Curative Biotechnology's board of directors comprises two types of representatives: Curative Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curative. The board's role is to monitor Curative Biotechnology's management team and ensure that shareholders' interests are well served. Curative Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curative Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Curative Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curative Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to
measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to
predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.